# Tumor Microenvironment Analysis Agent

**ID:** `biomedical.clinical.tumor_microenvironment`
**Version:** 1.0.0
**Status:** Production
**Category:** Clinical / Oncology / Tumor Microenvironment

---

## Overview

The **Tumor Microenvironment Analysis Agent** provides comprehensive characterization of the tumor microenvironment (TME) from multi-modal data sources including bulk RNA-seq, single-cell RNA-seq, spatial transcriptomics, and digital pathology. The TME plays a critical role in tumor progression, metastasis, and response to immunotherapy.

This agent integrates AI-powered deconvolution, immune phenotyping, and spatial analysis to deliver clinically actionable TME insights for immunotherapy patient selection and treatment optimization.

---

## Key Capabilities

### 1. TME Cell Type Deconvolution

| Method | Data Type | Output | Best For |
|--------|-----------|--------|----------|
| **CIBERSORTx** | Bulk RNA-seq | 22 immune cell types | Standard profiling |
| **TIMER2.0** | Bulk RNA-seq | 6 immune cell types | Pan-cancer |
| **xCell** | Bulk RNA-seq | 64 cell types | Comprehensive |
| **MCP-counter** | Bulk RNA-seq | 10 cell populations | Robust signatures |
| **EPIC** | Bulk RNA-seq | Cancer + immune | Tumor purity aware |
| **quanTIseq** | Bulk RNA-seq | 10 immune + cancer | Absolute fractions |

### 2. Immune Phenotyping

| Phenotype | Characteristics | Immunotherapy Response |
|-----------|-----------------|----------------------|
| **Immune-inflamed** | High TILs, IFN-γ signature | Best (40-60% response) |
| **Immune-excluded** | TILs at margin, stromal barrier | Moderate (15-25%) |
| **Immune-desert** | Low TILs, cold tumor | Poor (<10%) |

### 3. TME Biomarkers

| Biomarker | Measurement | Clinical Use |
|-----------|-------------|--------------|
| **PD-L1 (CPS/TPS)** | IHC | IO eligibility |
| **TMB** | WES/Panel | IO response prediction |
| **MSI-H/dMMR** | IHC/NGS | IO eligibility |
| **TIL density** | H&E/IHC | Prognostic |
| **IFN-γ signature** | RNA-seq | IO response |
| **GEP score** | 18-gene | Pembrolizumab response |

### 4. rT(I)ME Platform

The RNA-based Tumor and Immune Micro-Environment (rT(I)ME) platform uses AI-based technology to:
- Identify responder populations to immunotherapy
- Profile comprehensive TME landscape
- Predict treatment outcomes

---

## Usage

### Example Prompt

```text
Perform comprehensive TME analysis for a metastatic melanoma patient being considered for immunotherapy.

Available data:
- Bulk RNA-seq (tumor biopsy)
- Whole exome sequencing
- H&E pathology slide
- PD-L1 IHC (TPS: 60%)

Tasks:
1. Deconvolve immune cell composition
2. Classify immune phenotype
3. Calculate immunotherapy biomarkers
4. Generate immune gene signatures
5. Predict immunotherapy response probability
6. Recommend optimal immunotherapy regimen
```

### Expected Output

```
## Tumor Microenvironment Analysis Report

### Sample Information
- **Cancer type:** Metastatic melanoma
- **Biopsy site:** Cutaneous metastasis
- **Prior therapy:** Treatment-naive
- **PD-L1 TPS:** 60% (positive)

### Immune Cell Deconvolution

#### CIBERSORTx Analysis (22 cell types)

**Lymphoid Compartment:**

| Cell Type | Fraction | Percentile | Interpretation |
|-----------|----------|------------|----------------|
| CD8+ T cells | 18.2% | 85th | High infiltration |
| CD4+ memory T cells | 12.4% | 72nd | Elevated |
| CD4+ naive T cells | 2.1% | 45th | Normal |
| Tregs | 3.8% | 62nd | Moderate |
| B cells naive | 4.2% | 68th | Elevated |
| B cells memory | 2.1% | 55th | Normal |
| Plasma cells | 1.8% | 48th | Normal |
| NK cells activated | 5.4% | 78th | High |
| NK cells resting | 1.2% | 35th | Low |

**Myeloid Compartment:**

| Cell Type | Fraction | Percentile | Interpretation |
|-----------|----------|------------|----------------|
| Macrophages M1 | 8.2% | 75th | Elevated (favorable) |
| Macrophages M2 | 4.6% | 42nd | Normal |
| Dendritic cells activated | 3.4% | 70th | Elevated |
| Dendritic cells resting | 1.1% | 38th | Normal |
| Monocytes | 2.8% | 52nd | Normal |
| Neutrophils | 3.2% | 45th | Normal |
| Mast cells | 1.4% | 40th | Normal |
| Eosinophils | 0.8% | 32nd | Normal |

**Stromal Compartment:**

| Cell Type | Fraction | Percentile | Interpretation |
|-----------|----------|------------|----------------|
| Fibroblasts (CAFs) | 8.4% | 55th | Normal |
| Endothelial cells | 4.2% | 48th | Normal |

**Tumor content:** 24.6% (estimated from residual)

### Immune Phenotype Classification

```
┌─────────────────────────────────────────┐
│        IMMUNE-INFLAMED                  │
│                                         │
│  High CD8+ T cell infiltration (18.2%) │
│  Strong IFN-γ signature (score: 8.4)   │
│  Active cytotoxic response             │
│  TILs distributed throughout tumor     │
└─────────────────────────────────────────┘
```

**Phenotype:** IMMUNE-INFLAMED (confidence: 0.92)
**Supporting evidence:**
- CD8+ T cells > 15% (threshold: 10%)
- IFN-γ GEP > 7.5 (threshold: 6.0)
- PD-L1 TPS 60% (threshold: 1%)

### Immunotherapy Biomarker Panel

| Biomarker | Value | Threshold | Status | Evidence Level |
|-----------|-------|-----------|--------|----------------|
| **PD-L1 TPS** | 60% | ≥1% | Positive | Level 1A |
| **TMB** | 23.4 mut/Mb | ≥10 | High | Level 1A |
| **MSI status** | MSS | MSI-H | Negative | Level 1A |
| **IFN-γ GEP** | 8.4 | ≥6.0 | High | Level 2B |
| **CD8+ TILs** | 18.2% | ≥10% | High | Level 2B |
| **M1/M2 ratio** | 1.78 | ≥1.0 | Favorable | Level 3 |

### Gene Expression Signatures

#### Immune-Related Signatures

| Signature | Score | Percentile | Interpretation |
|-----------|-------|------------|----------------|
| **T cell inflamed (GEP-18)** | 8.4 | 88th | High |
| **IFN-γ signature** | 7.2 | 82nd | High |
| **Cytolytic activity** | 6.8 | 79th | High |
| **Antigen presentation** | 5.9 | 71st | Elevated |
| **T cell exhaustion** | 4.2 | 65th | Moderate |

#### Resistance Signatures

| Signature | Score | Percentile | Concern |
|-----------|-------|------------|---------|
| **TGF-β signature** | 3.1 | 35th | Low (favorable) |
| **Wnt/β-catenin** | 2.4 | 28th | Low (favorable) |
| **MDSC signature** | 3.8 | 42nd | Normal |
| **Angiogenesis** | 4.1 | 48th | Normal |

### Spatial TME Characterization (from H&E)

**AI-Pathology Analysis:**

| Feature | Value | Clinical Relevance |
|---------|-------|-------------------|
| TIL score (Salgado) | 40% | High infiltration |
| TIL distribution | Intratumoral | Favorable |
| Tertiary lymphoid structures | 3 present | Favorable |
| Necrosis | 5% | Minimal |
| Tumor-stroma ratio | 65:35 | Tumor-dominant |

### Immunotherapy Response Prediction

#### Multi-Feature AI Model

| Model | Predicted Response | Probability | Confidence |
|-------|-------------------|-------------|------------|
| **Ensemble (proprietary)** | Responder | 0.78 | High |
| **GEP-based** | Responder | 0.82 | High |
| **TMB-based** | Responder | 0.71 | Moderate |
| **Combined biomarker** | Responder | 0.84 | High |

**Overall prediction:** LIKELY RESPONDER (78% probability)

### Treatment Recommendation

#### First-Line Immunotherapy Options

| Regimen | Rationale | Expected Response | Evidence |
|---------|-----------|-------------------|----------|
| **Pembrolizumab** | PD-L1 ≥1%, high GEP | 45-50% ORR | KEYNOTE-006 |
| **Nivolumab + Ipilimumab** | TMB-high, inflamed | 50-60% ORR | CheckMate-067 |
| **Nivolumab monotherapy** | PD-L1 positive | 40-45% ORR | CheckMate-066 |

**Recommended regimen:** Nivolumab + Ipilimumab (CheckMate-067)
- Rationale: Inflamed TME + high TMB supports combination
- Higher response rate in biomarker-favorable tumors
- Consider single-agent if toxicity concerns

### Monitoring Recommendations

| Timepoint | Assessment | Biomarker |
|-----------|------------|-----------|
| Baseline | Current analysis | All |
| Week 12 | Response assessment | CT + ctDNA |
| If PD | Rebiopsy | Full TME repeat |
| If acquired resistance | Rebiopsy | Resistance mechanisms |

### Resistance Risk Factors to Monitor

| Factor | Current Status | Risk |
|--------|---------------|------|
| β-catenin activation | Low | Low |
| TGF-β signature | Low | Low |
| JAK1/2 mutations | Not detected | Low |
| B2M loss | Not detected | Low |
| PTEN loss | Not detected | Low |
```

### LLM Agent Integration

```python
@tool
def deconvolve_tme(
    expression_data: str,
    method: str = "cibersortx",
    tumor_purity: float = None
) -> str:
    """
    Deconvolves TME cell composition from bulk RNA-seq.

    Args:
        expression_data: Path to gene expression matrix
        method: Deconvolution method (cibersortx, timer, xcell, epic)
        tumor_purity: Known tumor purity (optional)

    Returns:
        Cell type fractions with confidence intervals
    """
    pass


@tool
def classify_immune_phenotype(
    tme_data: str,
    cancer_type: str = None
) -> str:
    """
    Classifies tumor immune phenotype.

    Args:
        tme_data: Path to TME deconvolution results
        cancer_type: Cancer type for context-specific thresholds

    Returns:
        Immune phenotype (inflamed/excluded/desert) with evidence
    """
    pass


@tool
def calculate_immune_signatures(
    expression_data: str,
    signatures: list[str] = ["ifng", "gep18", "cytolytic"]
) -> str:
    """
    Calculates immune gene expression signatures.

    Args:
        expression_data: Path to gene expression data
        signatures: Signatures to calculate

    Returns:
        Signature scores with percentile rankings
    """
    pass


@tool
def predict_immunotherapy_response(
    tme_data: str,
    biomarkers: dict,
    cancer_type: str
) -> str:
    """
    Predicts immunotherapy response probability.

    Args:
        tme_data: Path to TME analysis
        biomarkers: Dict of biomarker values (TMB, PD-L1, MSI)
        cancer_type: Cancer type

    Returns:
        Response prediction with confidence
    """
    pass


@tool
def recommend_immunotherapy(
    tme_profile: str,
    patient_factors: dict
) -> str:
    """
    Recommends optimal immunotherapy regimen.

    Args:
        tme_profile: Path to TME analysis
        patient_factors: Age, comorbidities, preferences

    Returns:
        Ranked therapy recommendations with rationale
    """
    pass
```

---

## Prerequisites

### Required Tools

| Tool | Version | Purpose |
|------|---------|---------|
| **CIBERSORTx** | Web/Docker | Deconvolution |
| **xCell** | R package | Comprehensive profiling |
| **TIMER2.0** | Web | Pan-cancer analysis |
| **MCP-counter** | R package | Robust signatures |

### Dependencies

```
pandas>=2.0
numpy>=1.24
scipy>=1.11
scikit-learn>=1.3
seaborn>=0.12
matplotlib>=3.7
```

---

## Methodology

### TME Analysis Pipeline

```
Tumor Sample
├── Bulk RNA-seq
├── WES (TMB)
├── IHC (PD-L1, TILs)
└── H&E pathology
    ↓
Data Processing
├── Gene expression normalization
├── Quality control
└── Batch correction
    ↓
TME Deconvolution
├── CIBERSORTx (22 cell types)
├── Cross-validation with xCell
└── Tumor purity estimation
    ↓
Immune Phenotyping
├── TIL quantification
├── Phenotype classification
└── Spatial distribution
    ↓
Biomarker Integration
├── PD-L1, TMB, MSI
├── Gene signatures
└── AI prediction models
    ↓
Clinical Recommendations
├── IO eligibility
├── Regimen selection
└── Monitoring plan
```

---

## Clinical Applications

### Immunotherapy Selection
- Patient stratification for checkpoint inhibitors
- Combination therapy rationale
- Predictive biomarker integration

### Resistance Mechanisms
- Primary resistance detection
- Acquired resistance monitoring
- Alternative therapy guidance

### Clinical Trials
- Patient enrichment strategies
- Correlative biomarker analysis
- Novel target identification

---

## Related Skills

- **Liquid Biopsy Agent:** ctDNA TME markers
- **Digital Pathology Agent:** H&E-based TIL scoring
- **Spatial Transcriptomics Agent:** Spatial TME analysis
- **Immunotherapy Response Agent:** Treatment prediction

---

## References

- **Chen & Mellman (2017):** "Elements of cancer immunity and the cancer-immune set point." *Nature*
- **Galon & Bruni (2019):** "Approaches to treat immune hot, altered and cold tumours with combination immunotherapies." *Nature Reviews Drug Discovery*
- [CIBERSORTx](https://cibersortx.stanford.edu/)
- [TIMER2.0](http://timer.cistrome.org/)

---

## Author

**MD BABU MIA**
*Artificial Intelligence Group*
*Icahn School of Medicine at Mount Sinai*
md.babu.mia@mssm.edu
